One such approach could involve chimeric antigen receptor engineering of T cells (CAR-T cells) targeting Ewing sarcoma cell-specific surface antigens, such as pregnancy-associated plasma protein-A (PAPP-A; Fig. 1D; refs. 23, 59). Here, PAPPA is linked to Ewing sarcoma.